Solid Tumor CAR-T Constraints

Solid tumor CAR-T constraints are the barriers that make [[CARTCellTherapy|CAR-T]] much harder in tissue-based cancers than in blood cancers, as described in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. Blood cancer cells circulate or have rich blood supply, so engineered T cells can encounter targets more directly. Solid tumors sit inside organs and tissue, where CAR-T cells must find, enter, survive, and keep killing within an adverse environment.

The episode highlights three layers of constraint. First is infiltration: immune cells must physically reach and penetrate the tumor. Second is scale: a large tumor may contain tens of billions of cancer cells, while infused CAR-T cells are far fewer and not all reach the target. Third is the Tumor Microenvironment, which suppresses immune activity and can exhaust or disable engineered cells after entry.

Key Claims

• Solid-tumor difficulty is not only a target-recognition problem; it is also an access, persistence, and local-environment problem.
• In Vivo CAR-T may lower manufacturing cost, but it does not automatically solve solid-tumor infiltration or immune suppression.
• The source treats solid tumors as the main future frontier because most cancer patients have solid tumors while current CAR-T successes are concentrated in blood cancers.
• Eureka Therapeutics is positioned through this source as a company working in the difficult solid-tumor branch.

Connections

• CAR-T Cell Therapy, In Vivo CAR-T, and Ex Vivo CAR-T Manufacturing - CAR-T routes affected by the constraint.
• Tumor Microenvironment - suppressive local setting inside solid tumors.
• Cancer Immune Recognition Problem - recognition problem that remains necessary but insufficient.
• [[LiuCheng|刘诚]] and Eureka Therapeutics - source viewpoint and company context.